Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAUNA trial of continuing versus stopping somatostatin analogues after progression in gastroenteropancreatic neuroendocrine tumors
NL-OMON60778Phase 4Recruiting
- Sponsor
- Antwerp University Hospital
- Start
- Aug 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of lanreotide in Gastroenteropancreatic Carcinoid Tumor (4 arms), sponsored by Antwerp University Hospital. Primary endpoints: Progression-free survival in PRRT substudy, Progression-free survival in targeted therapy substudy and 2 more. Started Aug 2023; status: recruiting.
02
Drugs
lanreotide
03
Conditions
Gastroenteropancreatic Carcinoid Tumor
Beyond the preview
Go deeper on NL-OMON60778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60778.